Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Total Non-Current Liabilities (2016 - 2025)

Vanda Pharmaceuticals' Total Non-Current Liabilities history spans 14 years, with the latest figure at $152.2 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 40.86% year-over-year to $152.2 million; the TTM value through Dec 2025 reached $152.2 million, up 40.86%, while the annual FY2025 figure was $152.2 million, 40.86% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $152.2 million at Vanda Pharmaceuticals, up from $124.1 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $152.2 million in Q4 2025 and bottomed at $72.9 million in Q1 2021.
  • The 5-year median for Total Non-Current Liabilities is $99.8 million (2024), against an average of $101.3 million.
  • The largest annual shift saw Total Non-Current Liabilities fell 9.08% in 2023 before it skyrocketed 40.86% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $84.5 million in 2021, then increased by 18.67% to $100.2 million in 2022, then dropped by 5.53% to $94.7 million in 2023, then increased by 14.12% to $108.1 million in 2024, then skyrocketed by 40.86% to $152.2 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Total Non-Current Liabilities are $152.2 million (Q4 2025), $124.1 million (Q3 2025), and $128.4 million (Q2 2025).